Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Partnership
BARDA Partners with ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
Details : The partnership aims to execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine compared to currently approved/authorised COVID-19 vaccines in the prevention of symptomatic, PCR confirmed SARS-CoV-2 infecti...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 13, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients
Details : Mallinckrodt has initiated a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE)" to collect real-world data on the use of INOmax® gas, for inhalation therapy in patients with respiratory complications associ...
Product Name : INOmax
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2020
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orbsen Therapeutics’ proprietary ORBCEL cellular therapy demonstrated the ability to mitigate the effects of ARDS by improving lung oxygenation.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 15, 2020
Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable